This move is archived. Current quotes and coverage live on the stock page.
Get BCT alerts:
Briacell Therapeutics Corp (BCT.TO) is seeing a notable rise in its stock price, gaining 3.38% in the last trading session.
Briacell closed at CA$3.98 after this increase, reflecting growing investor confidence in the company’s progress and strategic developments.
Advertisement
Briacell Therapeutics Corp
BCT.TO
BCT.TO
Briacell Therapeutics Corp
WealthAwesomeMarket cap
$43.41M
52W high
$20.40
52W low
$3.68
1W change
+2.46%
Beta
1.53
Analyst Price Targets
Based on analyst covering BCT
Wall Street analysts forecast BCT stock price to rise 300.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$20.00
+300.8% Upside
Current Price
C$4.99
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BCT's historical volatility
30-Day Vol
81.5%
Annualized
90-Day Vol
87.2%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$5.97
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$5.30 | C$4.00 – C$7.02 |
| 60 trading days | C$5.62 | C$3.78 – C$8.37 |
| 90 trading days | C$5.97 | C$3.67 – C$9.71 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: For Canadian investors, Briacell's recent performance might indicate a rising interest in its innovative approaches to cancer treatment, especially its personalized immunotherapy solutions.
Briacell's Market Cap Reaches CA$33.49 Million
With a market cap of CA$33.49 million, Briacell Therapeutics Corp is positioning itself as a key player in the biotech industry, particularly in personalized medicine.
Bull case
The recent rise in Briacell's stock price likely stems from its ongoing advancements in cancer therapies. Investors are looking for growth in the biotech sector, and Briacell's innovations are attracting attention.
Bear case
Even with this positive momentum, investors should be cautious. The biotech sector can be volatile, and any setbacks in clinical trials or regulatory approvals could negatively affect stock performance.
Recent Performance Overview
Advertisement
Briacell's stock has gained 3.38% in the last trading session, closing at CA$3.98. This performance reflects positive investor sentiment towards the company’s innovative cancer therapies, which are increasingly relevant in today’s healthcare landscape.
What’s Driving the Stock Up?
Briacell's recent stock price increase is linked to its ongoing efforts in developing personalized immunotherapy solutions. As the company continues to make progress in its clinical trials, investor confidence may grow, leading to more interest and trading activity in its shares. For more details on Briacell's developments, check out the BCT.TO stock page.
Investor Considerations
While the recent gains are promising, investors should remember the risks associated with biotech investments. The sector is known for its volatility, and any negative news regarding clinical trials or regulatory hurdles could quickly reverse gains. Staying informed about Briacell's progress and market conditions is crucial for potential investors.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
